Scientists evaluate new treatments of Alzheimer’s disease on neurons derived from iPSCs from patients.
Alzheimer’s disease is the leading cause of dementia, and has affected approximately 48 million people worldwide. Despite decades of research, we have yet to come up with a successful treatment. One major challenge in drug development for neurological diseases is access to a clinically relevant disease model. As stated in a recent WSJ article, results from animal testing often do not predict well what will happen in humans . As a result, many promising drug candidates have been removed from further development because of safety concerns or lack of efficacy.